Set and Setting in Psychedelic-Assisted Therapy: Why Context Modulates the Medicine

In psychedelic-assisted therapy, the substance is one variable; the context around the substance is another, and it is not minor. The phrase clinicians use for that context is set and setting — set is the patient's mindset coming into the dosing session, and setting is the physical, social, and clinical environment in which the experience takes place. The same dose of the same substance, given to the same person on different days in different rooms with different people, can produce dramatically different experiences. This article is a Canadian guide to what set and setting actually mean clinically, why they matter, what the evidence says, how ATMA CENA constructs both deliberately, and what patients themselves can do to optimize the part of "set" that is in their hands.

Key takeaways

• Set and setting is a clinical framework, not a vibe. Originally articulated by Leary, Litwin and Metzner (1963) and re-formalized by Hartogsohn (2017, J Psychopharmacol, PMID 28443452), it is one of the better-evidenced organizing concepts in psychedelic medicine.
• "Set" = the patient's mindset, expectations, intentions, personality, and history coming into the session. It is partly stable and partly built deliberately during the preparation phase.
• "Setting" = the physical, social, clinical, and cultural environment in which the experience takes place. It is engineered by the clinic, with patient input.
• Dose-response is real, but context substantially modulates it. The same dose in different contexts produces different experiences and different safety profiles.
• Two-clinician model: MAPP1/MAPP2 (Mitchell 2021/2023) and Goodwin 2022 COMP001-style protocols use two clinicians in the dosing room as a structural setting variable.
• Music is a key set/setting variable, with a research literature (Kaelen et al. 2018) showing measurable contributions to subjective experience.
• Necessary, not sufficient. Strong set and setting supports safety and quality of the experience; it does not predict response and does not replace the substance, the dose, the screening, or the integration work.

Where the framework comes from

The phrase "set and setting" enters the modern psychedelic literature through Timothy Leary, George Litwin and Ralph Metzner's 1963 paper Reactions to psilocybin administered in a supportive environment (J Nerv Ment Dis, PMID 14087676). Leary and colleagues observed that the subjective effects of psilocybin varied widely across participants in ways that were not explained by dose alone, and that two clusters of variables seemed to predict variation: the participant's psychological state ("set") and the environment of administration ("setting").

The framework was largely sidelined during the prohibition era of psychedelic research, then re-formalized for the modern clinical context by Ido Hartogsohn's 2017 article Set and Setting, Psychedelics and the Placebo Response (Journal of Psychopharmacology, PMID 28443452) and his subsequent 2017 review in Drug Science, Policy and Law, Constructing drug effects: A history of set and setting. Hartogsohn's contribution was to argue, with reference to the history of psychopharmacology and contemporary placebo research, that set and setting are not ancillary to the drug effect — they are constitutive of it. The pharmacology supplies a non-ordinary state; the set and setting shape what that state becomes for the patient.

This framework is now embedded across mainstream psychedelic-assisted therapy protocols: the Mithoefer / Mitchell MAPP1 and MAPP2 MDMA-AT manuals (Mitchell 2021, PMID 33972795; Mitchell 2023, PMID 37640273), the Compass Pathways COMP001 psilocybin protocol (Goodwin 2022, PMID 36322843), the Carhart-Harris Imperial College psilocybin trials, and contemporary ketamine-assisted psychotherapy literature (Dore 2019, PMID 30917760; Mathai 2023). Reputable Canadian clinics treat set and setting as engineerable clinical variables rather than atmosphere.

What "set" actually means

"Set" is shorthand for everything the patient brings into the dosing room from inside their own mind: mindset, current mental state, expectations, intentions, personality, and history. It is partly stable and partly modifiable, and the modifiable parts are the explicit work product of the preparation phase.

Components of "set" in current clinical practice:

• Psychological readiness. Has the patient understood what the substance does, what to expect, what is normal, and what would be a signal to communicate? This is built in preparation.
• Trust in the clinical team. Therapeutic alliance with the people who will be in the room when the medicine takes effect. Alliance is not optional decoration; it is the variable a patient leans on if difficult material arises.
• Clarity about intentions. What the patient is hoping to explore, change, or sit with. Intentions are reference points, not outcome promises.
• Expectations management. What the patient has been told the medicine will and will not do. Over-promised expectations distort set; honest, evidence-grounded expectations stabilize it.
• Comfort with vulnerability. The willingness to allow material to surface. This is partly trait, partly trained in preparation, partly a function of trust in the team.
• Trauma history and triggers. Specific somatic, relational, and contextual triggers documented in preparation so the team can respond if they emerge during dosing.
• Acute state. Sleep, hydration, food, mood, and the events of the prior 48 hours all enter set. Patients who arrive sleep-deprived, hungry, or in acute conflict are working from a degraded baseline.

Set is not a personality test the patient passes or fails. It is the constellation a clinician maps and works with, and that the patient can deliberately shape in the days and weeks before dosing.

What "setting" actually means

"Setting" is everything outside the patient's mind: the physical, social, clinical, and cultural environment of the dosing session. Setting is the part the clinic engineers, with patient input on the variables that personalize meaningfully.

Components of "setting" in current clinical practice:

• Physical setting. Room aesthetics, lighting (typically dim, warm, indirect), temperature, comfort of the recliner or couch, blankets, pillows, art on the walls, view if any, smells. Hospital fluorescents and bare white walls are unfavourable settings; deliberately designed therapeutic rooms are favourable ones.
• Music. Curated audio is a setting variable in its own right (see below). The choice between standardized and personalized playlists is a clinical and patient-preference decision.
• Social setting. Who is in the room. The two-clinician model (see below) is a setting choice. Whether a support person is allowed in for parts of the session is a setting choice.
• Clinical setting. Medical safety equipment — blood pressure cuff, pulse oximeter, emergency medications — is present, but how visible it is to the patient is a setting choice. In most modern protocols, monitoring equipment is functional but unobtrusive.
• Cultural setting. Ritual elements where the patient asks for them and they are clinically appropriate — a meaningful object, a brief grounding practice, a chosen reading, a moment of silence at the start. Cultural elements are patient-led, never imposed.
• Privacy and confidentiality. No interruptions, no inadvertent observers, phones silenced, door signage in place, charting completed before the session begins.

A well-engineered setting is not lavish; it is intentional. Every variable has been considered and either chosen or deliberately neutralized.

Why set and setting matter — the evidence

The strong claim in modern psychedelic medicine is that dose-response is real but set and setting substantially modulate it (Hartogsohn 2017; Carhart-Harris and Friston 2019; Preller and Vollenweider 2018, PMID 28025814). Three lines of evidence support this.

1. Subjective experience varies far more than dose alone predicts. Within a fixed dose, the spread of subjective intensity, emotional tone, and content is substantial. The variables that predict that spread are predominantly psychological state and contextual variables, not pharmacokinetic ones (Carbonaro 2016, PMID 27909164; Preller and Vollenweider 2018).

2. Adverse-experience clustering is contextual. Carbonaro et al. (2016) surveyed individuals who reported challenging psilocybin experiences. The clustering of distress and prolonged adverse effect was associated with poor preparation, unsupportive setting, and inadequate sitting more than with dose. Adverse events in the controlled-trial literature similarly concentrate where preparation and setting were suboptimal.

3. Same substance, different context, different outcome. Comparative work across clinical and recreational contexts — and between MAPS-style and less structured MDMA delivery, between supervised psilocybin and unsupervised use, between ketamine-as-infusion and ketamine-as-psychotherapy (Dore 2019; Mathai 2023) — repeatedly shows that the same pharmacology under different set and setting produces different experiential and clinical outcomes.

The corollary that follows is uncomfortable but worth stating: set and setting affect safety as well as therapeutic value. Inadequate set and setting raises the probability of acute panic, prolonged distress, retraumatization, and the kind of "bad trip" outcome that has long-tail psychological consequences. This is a clinical reason — not an aesthetic one — to take set and setting seriously.

The two-clinician model

One of the most studied setting variables is how many clinicians are in the room. The MAPS-developed MDMA-AT manual used in Mitchell 2021 MAPP1 (PMID 33972795) and Mitchell 2023 MAPP2 (PMID 37640273) specifies a co-therapy pair in the dosing room. The Compass Pathways COMP001 protocol (Goodwin 2022, PMID 36322843) similarly pairs a lead therapist with a co-therapist or sitter. The rationale is well-articulated in the MAPS manual:

• Continuous presence across long sessions (MDMA dosing sessions run 6–8 hours; psilocybin 6–8 hours) without single-clinician fatigue
• Two perspectives during clinically ambiguous moments
• Coverage for breaks and any in-session medical needs
• Modeling of safe relational dynamics — particularly relevant for trauma-related work
• Reduced risk of boundary violation — a structural safeguard built into the setting itself

The two-clinician model is more resource-intensive and is one reason MDMA-AT and high-dose psilocybin are clinic-based. Ketamine-assisted psychotherapy ranges in staffing from a single trained clinician with a sitter to full co-therapy depending on protocol, substance form, and patient profile.

Music as a key set/setting variable

Music is not background. In modern psychedelic-assisted therapy protocols, the playlist is part of the medicine. The Imperial College London group (Kaelen et al. 2018, Psychopharmacology) demonstrated that music chosen for psilocybin sessions made measurable contributions to subjective experience, including emotional response, sense of meaningfulness, and degree of mystical-type experience. The MAPS MDMA-AT manual specifies a curated playlist with deliberate emotional arc; the COMPASS psilocybin protocol uses a Compass-developed playlist; ketamine-assisted psychotherapy practices vary.

The clinical question patients face is standardized vs personalized:

• Standardized playlists (e.g., the Imperial / COMPASS playlists) are designed across many sessions, with deliberate arcs from gentle opening through peak to landing. They have predictable emotional contours that the team is trained to anticipate.
• Personalized playlists allow patients to bring music with personal meaning — but personal meaning cuts both ways and can introduce associations the patient did not anticipate during dosing.

Most modern protocols default to standardized or semi-standardized playlists, with patient input on whether vocals, language, or specific genres should be excluded. Patient autonomy on music is real but not unlimited; the team's clinical judgment about emotional pacing remains in play.

Eye-mask, inward focus, and non-directive presence

Two further structural setting features are worth naming explicitly.

Eye-mask and inward focus. Most psilocybin and MDMA-AT protocols invite patients to wear an eye-mask for substantial portions of the dosing session and to direct attention inward rather than outward. The eye-mask is a setting choice that reduces visual stimulation and supports the inner-directed approach. Patients can remove it at any time.

Therapist non-directive presence. The clinician's role during dosing is predominantly non-directive: present, available, calm, supportive, but not steering content. The MAPS manual is explicit that the therapist follows the patient's process rather than leading it. This is a deliberate setting choice — directive interventions during dosing tend to disrupt the inward arc the medicine and the eye-mask have set up.

These features are not universal. Some KAP protocols, particularly with lower ketamine doses, are more conversational. The structural choice between inward-directed and dialogic dosing is part of the setting design and should be discussed with the patient in preparation.

Risks of poor set and setting

When set and setting are inadequate, the documented risk profile shifts:

• Acute panic and overwhelm during dosing — particularly with high-dose psilocybin and MDMA in unfamiliar or unsupportive environments
• Prolonged distress in the days and weeks following dosing — Carbonaro 2016 documents this clustering
• Retraumatization — when trauma material surfaces and the team or environment cannot hold it safely
• "Bad trip" outcomes with long-tail psychological sequelae — uncommon in well-prepared, well-set clinical contexts; more common in unstructured or unsupervised use
• Disrupted integration — experiences that occurred in unsafe settings can be harder for the patient to make use of after the fact

These are not theoretical. They are why every component of set and setting is treated as clinical work in modern protocols rather than as production design.

How ATMA CENA constructs set and setting

ATMA CENA's clinical environment is designed against the framework above.

Setting — physical and clinical. ATMA CENA's dosing rooms are designed for the inward-directed approach: dim, warm lighting; comfortable recliner-style seating with blankets and pillows; neutral, calming aesthetics; functional but unobtrusive medical monitoring; private bathroom access; sound system designed for fidelity at quiet volumes. Rooms are insulated against interruption, and clinic protocols protect privacy across the session arc.

Setting — social. ATMA CENA's dosing protocols are calibrated to substance and patient: psilocybin and MDMA-AT under SAP follow the two-clinician model in line with COMP001 and MAPP1/MAPP2; ketamine-assisted psychotherapy staffing follows substance, route, dose, and patient-specific clinical judgment. The team a patient meets in preparation is the team in the dosing room and through integration, wherever clinically possible.

Setting — clinical. Vitals monitoring is active but visually unobtrusive; emergency medications and protocols are present but not displayed. The clinician's posture is non-directive, in line with the manualized approach across MAPP and COMPASS protocols.

Setting — cultural and personal. Patients are invited in preparation to identify a meaningful object, a chosen reading, a brief grounding practice, or a similar element if they want one. These elements are patient-led, never imposed, and clinically reviewed.

Set — psychological readiness. The work of stabilizing "set" sits in preparation: alliance-building, education, intention-setting, anchor-skills practice, and contraindication screening. See the preparation-phase article for the structure.

Set — coordinated care. ATMA CENA's coordinated care model is particularly relevant to "set." Where a patient already has an established therapist, psychiatrist, or family physician, the existing relationship anchors trust. ATMA CENA's coordinated care model layers psychedelic-assisted treatment on top of that relationship rather than replacing it. From a set-and-setting perspective, an existing therapeutic alliance is one of the strongest sources of stable "set" a patient can bring into a dosing session.

What patients can do to optimize their own "set"

The setting is engineered by the clinic. The set is a collaboration. Patients have meaningful input on the components of set that are theirs.

• Sleep. Aim for two consecutive nights of adequate sleep before the dosing session. Sleep deprivation is a degraded baseline.
• Hydration and food. Follow your clinic's instructions on the day of dosing. For most psilocybin and MDMA protocols this includes a light meal a few hours before.
• Reduce stimulant load. Caffeine on the morning of dosing is usually fine; ramped-up caffeine, nicotine, or stimulants beyond your baseline are not.
• Substance use. Alcohol the night before is generally discouraged. Recreational substance use in the 48 hours before dosing is a clinical concern; raise it honestly with your team.
• Conflict and acute stress. Where possible, avoid high-conflict conversations or peak-stress events in the 48 hours before dosing.
• Set your intentions. Re-read your intentions the day before. They are reference points, not goals.
• Communicate any change in your state. Sleep, mood, recent events, new medications, illness — tell your team. A small communication before dosing is far better than an unaddressed factor during it.
• Bring what you've been told you can bring. A meaningful object, a chosen item of clothing, a reading — within the clinic's protocol.
• Trust the protocol you co-built in preparation. The work of preparation is the dosing-day script. Trust it.

These are the levers patients have. They are not large in isolation; together they are how a patient enters the session with the strongest "set" they can assemble.

What set and setting does NOT do

• Set and setting is necessary, not sufficient. Substance, dose, screening, and integration all matter. Excellent set and setting does not rescue an inappropriate substance choice or inadequate screening.
• Strong set and setting does not guarantee a strong outcome. Goodwin 2022 COMP001 showed 37% response and 29% remission at the 25 mg psilocybin dose at week 3 in TRD — meaningful, but partial, and inside a tightly engineered set-and-setting envelope.
• Set and setting cannot make a patient eligible. Contraindications are clinical (psychotic-disorder personal/family history, uncontrolled cardiovascular disease, pregnancy, certain medication interactions) and are not modulated by environment.
• Set and setting cannot substitute for the substance. The pharmacology supplies the non-ordinary state; the framework shapes what the state becomes. Removing the substance does not leave a therapy that works the same way.

Frequently asked questions

Where does the phrase "set and setting" come from? The framework is generally credited to Timothy Leary, George Litwin and Ralph Metzner's 1963 paper Reactions to psilocybin administered in a supportive environment (PMID 14087676), and was re-formalized for modern clinical practice by Ido Hartogsohn's 2017 work, particularly Set and Setting, Psychedelics and the Placebo Response in the Journal of Psychopharmacology (PMID 28443452).

What's the difference between set and setting? Set is internal — the patient's mindset, expectations, intentions, personality, and history coming into the session. Setting is external — the physical, social, clinical, and cultural environment in which the experience takes place. Both matter; they are engineered jointly through preparation and the clinic's protocol.

Why are there usually two clinicians in the dosing room? The two-clinician (co-therapy) model is built into the MAPS MDMA-AT manual used in Mitchell 2021 MAPP1 and Mitchell 2023 MAPP2, and the COMPASS COMP001 psilocybin protocol (Goodwin 2022). It supports continuous presence across long sessions, two-perspective clinical judgment, coverage for breaks, and structural safeguards in trauma-related work. KAP staffing varies by substance, dose, and patient.

Why is music a clinical variable? Because the evidence — including Kaelen et al. 2018 — shows that music makes measurable contributions to subjective experience during psilocybin sessions, and the MAPS, COMPASS and Imperial protocols treat curated audio as part of the therapy. Most modern protocols use standardized or semi-standardized playlists with patient input on exclusions.

Can I bring my own music? Sometimes, with clinical review. Most modern protocols default to standardized playlists because their emotional arcs are predictable for the team. Personalized music can introduce associations a patient did not anticipate during dosing. The decision is made in preparation.

Why an eye-mask? The eye-mask supports the inward-directed approach used in psilocybin and MDMA-AT protocols. It reduces visual stimulation and helps direct attention inward rather than outward. Patients can remove it at any time.

Is the therapist supposed to talk to me during the session? In most psilocybin and MDMA-AT protocols, the dominant clinical posture is non-directive: present, available, calm, supportive, but not steering content. The therapist follows the patient's process rather than leading it. KAP protocols vary; lower-dose ketamine sessions can be more dialogic. This is discussed in preparation.

What if I don't like the room or the music? Raise it in preparation. Setting choices are clinical, but patient input on the variables that personalize meaningfully — music exclusions, lighting, blankets, meaningful objects — is built into the model.

Does set and setting matter as much for ketamine as for psilocybin or MDMA? The literature increasingly says yes, with calibration. Dore 2019 (PMID 30917760) and Mathai 2023 document differences between ketamine-as-infusion-only and ketamine-with-psychotherapy. Set and setting effects are most studied at higher doses and longer-duration substances, but the principle generalizes.

Can my existing therapist contribute to my "set"? Yes — this is a core argument for ATMA CENA's coordinated care model. An existing therapeutic alliance is one of the strongest sources of stable "set" a patient can bring into a dosing session. ATMA CENA's coordinated care model keeps your existing therapist primary while layering psychedelic-assisted treatment on top.

If set and setting are so important, can a perfect environment make the medicine work? No. Set and setting is necessary, not sufficient. Substance, dose, screening, preparation, and integration all matter. Excellent set and setting supports safety and quality of the experience; it does not predict response and does not replace the clinical work surrounding it.

Compliance disclaimer

This article is educational. Psilocybin and MDMA are Schedule III and Schedule I controlled substances in Canada respectively; clinical access in Canada is via Health Canada's Special Access Program on a case-by-case basis. Ketamine is a Health Canada-approved anaesthetic; psychiatric use is off-label and within Canadian off-label prescribing principles. Esketamine (Spravato) is Health Canada-approved for treatment-resistant depression. Nothing in this article should be construed as a clinical recommendation for a specific individual; clinical decisions belong with a qualified prescribing physician.

Sources

1. Leary T, Litwin GH, Metzner R. (1963). Reactions to psilocybin administered in a supportive environment. Journal of Nervous and Mental Disease, 137:561-573. PMID: 14087676.
2. Hartogsohn I. (2017). Set and Setting, Psychedelics and the Placebo Response: An Extra-Pharmacological Perspective on Psychopharmacology. Journal of Psychopharmacology, 31(8):1259-1267. PMID: 28443452.
3. Hartogsohn I. (2017). Constructing drug effects: A history of set and setting. Drug Science, Policy and Law, 3:1-17.
4. Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (MAPP1). Nature Medicine, 27(6):1025-1033. PMID: 33972795.
5. Mitchell JM, Ot'alora G M, van der Kolk B, et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial (MAPP2). Nature Medicine, 29(10):2473-2480. PMID: 37640273.
6. Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (COMP001). New England Journal of Medicine, 387(18):1637-1648. PMID: 36322843.
7. Kaelen M, Giribaldi B, Raine J, et al. (2018). The hidden therapist: evidence for a central role of music in psychedelic therapy. Psychopharmacology, 235(2):505-519. PMID: 29396616.
8. Carbonaro TM, Bradstreet MP, Barrett FS, et al. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, 30(12):1268-1278. PMID: 27909164.
9. Carhart-Harris RL, Bolstridge M, Rucker J, et al. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry, 3(7):619-627. PMID: 27210031.
10. Preller KH, Vollenweider FX. (2018). Phenomenology, Structure, and Dynamic of Psychedelic States. Current Topics in Behavioral Neurosciences, 36:221-256. PMID: 28025814.
11. Dore J, Turnipseed B, Dwyer S, et al. (2019). Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy. Journal of Psychoactive Drugs, 51(2):189-198. PMID: 30917760.
12. Health Canada — Special Access Program: https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access.html

Related articles

• The Preparation Phase of Psychedelic-Assisted Therapy
• The Integration Phase of Psychedelic-Assisted Therapy
• What to Expect at Your First Psychedelic-Assisted Therapy Session
• The Health Canada SAP Application Process — Complete Guide
• ATMA CENA's coordinated care model — how ATMA CENA layers psychedelic-assisted therapy onto an existing therapeutic relationship
• Ketamine Therapy in Canada
• Psilocybin Therapy in Canada
• MDMA-Assisted Therapy in Canada

Last updated: 2026-05-06